Supernus Pharmaceuticals Inc. (SUPN)
Россия
  • Россия
  • Украина

Supernus Pharmaceuticals Inc. (SUPN)

Contact Details

1550 E Gude Dr, Rockville, Maryland, USA 20850-1339
(301) 838-2500
1550 E Gude Dr, Rockville, Maryland, USA 20850-1339

General Information

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Contact Information

Phone(301) 838-2500
Website 1http://www.supernus.com
Thomson Reuters PermID4297350707

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO, President and Secretary$1,651,1332014-36.2%
CFO and Vice President$728,6152014-5.3%
Chief Medical Officer and Divisional Executive VP$741,945201428.4%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsOctober 01, 2013$0
Department of Veterans AffairsDrugs and BiologicalsSeptember 10, 2014$0

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$144 million
Employees344

Ownership

Ticker SymbolSUPN
ExchangeNASDAQ Global Market
Year Founded2005

Stocks

Previous Close16.55
Open16.56
Bid16.47 x 200
Ask16.52 x 300
Day`s Range16.34 - 16.60
52-Week Range10.13 - 21.26
Average Volume (1M)792,831
Forward P/E26.33x
Trailing P/E55.73x
Beta1.76x
Market Cap.$825.97 Million
Last Dividend Amount0
1y Target Price Est.24.4

Pre-IPO

Summary of Form-D Filings

    Filing History

  • Supernus Pharmaceuticals Inc. has filed 2 Form Ds since 2008. Of these filings, 1 has been for a unique offering.
  • Through these filings, they have raised $30,000,000, and reported $0 remaining.
  • They have not paid finder`s fees or sales commissions in connection with these offerings.
  • They have not used any of the proceeds from its offerings to pay officers or directors.
  • The types of securities they have issued are Debt.
  • They have relied on the following exemptions in past filings Rule 506.

    Analysis of Past Filings

  • Supernus Pharmaceuticals Inc. has filed about as many filings as an average company in the Pharmaceuticals category.
  • They have had about as many unique offerings as an average company in the Pharmaceuticals category.
  • The total amount raised they have raised is 908% higher than the average for a company in the Pharmaceuticals category.

Form-D Filings

Filing DateFiling TypeTotal Offering AmountTotal Amount RaisedTotal Remaining For Sale
February 16, 2012Amendment$30,000,000$30,000,000$0
February 02, 2011New$25,000,000$15,000,000$10,000,000

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue42,65638,58635,05228,133
Cost of Revenue2,7952,2481,7621,618
Gross Profit39,86136,33833,29026,515
Research Development9,4459,1296,8783,683
Selling General and Administrative23,56622,90023,33619,402
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses35,80634,27731,97624,703
Other Income/Expenses Net----
Earnings Before Interest and Taxes6,8504,3093,0763,430
Interest Expense225292331381
Income Before Tax7,0464,2802,667979
Income Tax Expense1745866262
Minority Interest----
Net Income from Continuing Ops6,8724,2222,005917
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income6,8724,2222,005917
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares6,8724,2222,005917